The ICHRA Moment Is Here — Are You Ready for It?

ICHRA is surging in popularity as an option for employer-sponsored insurance to access the individual market, as employers rethink traditional group plans with unpredictable renewal rates and employees seek personalized healthcare. Here’s a closer look at why investors and politicians are eyeing ICHRA. The post The ICHRA Moment Is Here — Are You Ready for It?…

Read More

Expanding Support for Mail-Based Naloxone Delivery

The opioid settlement funds provide a crucial opportunity to get increased state or municipal funding behind mail-based naloxone delivery. Through partnering with existing organizations that already have robust infrastructure in place and substantial experience in mail-based naloxone municipalities can scale efforts efficiently. The post Expanding Support for Mail-Based Naloxone Delivery appeared first on MedCity News.

Read More

Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition

Regulus Therapeutics drug farabursen is a potential first-in-class treatment for a rare kidney disease whose only FDA-approved therapy introduces severe toxicity risks. Farabursen is joining a Novartis drug lineup spanning several therapies for rare renal disorders. The post Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition appeared first on MedCity News.

Read More